PURPOSE: Methylphenidate (MPH) ameliorates attention problems experienced by some cancer survivors in the short term, but its long-term efficacy is unproven. PATIENTS AND METHODS: This study investigates the long-term effectiveness of maintenance doses of MPH in survivors of childhood brain tumors (n = 35) and acute lymphoblastic leukemia (n = 33) participating in a 12-month MPH trial. Measures of attention (Conners' Continuous Performance Test [CPT], Conners' Rating Scales [CRS]), academic abilities (Wechsler Individual Achievement Test [WIAT]), social skills (Social Skills Rating System [SSRS]), and behavioral problems (Child Behavior Checklist [CBCL]) were administered at premedication baseline and at the end of the MPH trial while on medication. A cancer control group composed of patients who were not administered MPH (brain tumor = 31 and acute lymphoblastic leukemia = 23) was assessed on the same measures 12 [corrected] months apart. RESULTS: For the MPH group, repeated measures analysis of variance revealed significant improvement in performance on a measure of sustained attention (CPT indices, P < .05); parent, teacher, and self-report ratings of attention (CRS indices, P < .05), and parent ratings of social skills or behavioral problems (SSRS and CBCL indices; P < .05). In contrast, the cancer control group only showed improvement on parent ratings of attention (Conners' Parent Rating Scale indices; P < .05) and social skills (SSRS and CBCL indices; P < .05). There was no significant improvement on the academic measure (WIAT) in either group. CONCLUSION: Attention and behavioral benefits of MPH for childhood cancer survivors are maintained across settings over the course of a year. Although academic gains were not identified, MPH may offer benefits in academic areas not assessed.
PURPOSE:Methylphenidate (MPH) ameliorates attention problems experienced by some cancer survivors in the short term, but its long-term efficacy is unproven. PATIENTS AND METHODS: This study investigates the long-term effectiveness of maintenance doses of MPH in survivors of childhood brain tumors (n = 35) and acute lymphoblastic leukemia (n = 33) participating in a 12-month MPH trial. Measures of attention (Conners' Continuous Performance Test [CPT], Conners' Rating Scales [CRS]), academic abilities (Wechsler Individual Achievement Test [WIAT]), social skills (Social Skills Rating System [SSRS]), and behavioral problems (Child Behavior Checklist [CBCL]) were administered at premedication baseline and at the end of the MPH trial while on medication. A cancer control group composed of patients who were not administered MPH (brain tumor = 31 and acute lymphoblastic leukemia = 23) was assessed on the same measures 12 [corrected] months apart. RESULTS: For the MPH group, repeated measures analysis of variance revealed significant improvement in performance on a measure of sustained attention (CPT indices, P < .05); parent, teacher, and self-report ratings of attention (CRS indices, P < .05), and parent ratings of social skills or behavioral problems (SSRS and CBCL indices; P < .05). In contrast, the cancer control group only showed improvement on parent ratings of attention (Conners' Parent Rating Scale indices; P < .05) and social skills (SSRS and CBCL indices; P < .05). There was no significant improvement on the academic measure (WIAT) in either group. CONCLUSION: Attention and behavioral benefits of MPH for childhood cancer survivors are maintained across settings over the course of a year. Although academic gains were not identified, MPH may offer benefits in academic areas not assessed.
Authors: A R Jadad; L Booker; M Gauld; R Kakuma; M Boyle; C E Cunningham; M Kim; R Schachar Journal: Can J Psychiatry Date: 1999-12 Impact factor: 4.356
Authors: Ronald T Brown; Robert W Amler; Wendy S Freeman; James M Perrin; Martin T Stein; Heidi M Feldman; Karen Pierce; Mark L Wolraich Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-06-14
Authors: Lauren E Cox; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Victoria W Willard; Lu Huang; Hui Zhang; Heather M Conklin Journal: Neurooncol Pract Date: 2015-03-13
Authors: Heather M Conklin; Kirsten K Ness; Jason M Ashford; Matthew A Scoggins; Robert J Ogg; Yuanyuan Han; Yimei Li; Julie A Bradley; Frederick A Boop; Thomas E Merchant Journal: J Int Neuropsychol Soc Date: 2019-04 Impact factor: 2.892
Authors: Katherine H Moyer; Victoria W Willard; Alan M Gross; Kelli L Netson; Jason M Ashford; Lisa S Kahalley; Shengjie Wu; Xiaoping Xiong; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Victoria W Willard; Heather M Conklin; Frederick A Boop; Shengjie Wu; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038